Specialities

Specialities

Bladder Cancer
Breast Cancer
Colorectal Cancer
COVID-19
Dermatologic Cancers
Diagnostics and Screening
Gastrointestinal Cancers
Genitourinary Cancer
Gynecologic Cancers
Hematology
Hematologic Malignancies
Head and Neck Cancer
Immunotherapy
Leukemia
Lymphoma
Multiple Myeloma
Ovarian Cancer
Pancreatic Cancer
Lung Cancer
Prostate Cancer
Renal Cancer
Endocrine Cancers
Pediatric Oncology
Policy
Sarcoma
Supportive Cancer Care
Soft Tissue Tumors
Neuro-oncology
Pathology
Radiology
Radiotherapy
Rare Diseases
Search

Trending Topic
3 mins

Trending Topic
Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

Foreword – touchREVIEWS in Oncology & Haematology, Volume 22, Issue 1, 2026

This issue of touchREVIEWS in Oncology & Haematology brings together a diverse collection of articles reflecting the growing complexity of cancer care and the continued evolution of precision medicine across tumour types. From rare malignancies and treatment-related challenges to emerging targeted therapies and novel biological insights, the contributions highlight both recent progress and the significant […]

Connect With Us:

Facebook
X (Twitter)
Instagram
Youtube
Linkedin
touchINFOGRAPHIC

CLL Essentials: Diagnosis, Informed Treatment Decisions and Risk Management

Topics Covered:
Leukemia Hematology Hematologic Malignancies
touchONCOLOGY

Check your Inbox

We've sent your certificate

Back to Activity
Close Popup
touchONCOLOGY

Thank you
for your Feedback!

Back to Activity
Close Popup

Video Navigation

Activity Overview

Overview

The four infographics in this activity provide a structured overview of chronic lymphocytic leukemia, including diagnosis and staging, treatment decision-making and risk management. The activity emphasizes the need to maximize efficacy while minimizing adverse events in each patient, with therapy discontinuation decisions based on response or toxicity. In addition, it provides key questions to consider when initiating a new line of therapy. The activity also focuses on risk management in the clinic, reviewing the pretreatment workup needed when considering BTK inhibitor therapy in patients with pre-existing cardiac morbidities, and providing strategies for reducing both infection and secondary cancers.

Learning Objectives

After watching this activity, participants should be better able to:

  • Integrate diagnostic criteria, disease staging and biomarker interpretation to inform clinical decisions
  • Apply evidence to guide decisions on treatment initiation, discontinuation and introduction of new lines of therapy
  • Evaluate cardiac comorbidity to guide safe initiation of BTK inhibitor therapy
  • Implement strategies to identify and mitigate the risks of infection and secondary cancers

Video Navigation

Add a Note

Note Time: 00:00
Save Note
touchONCOLOGY
touchINFOGRAPHIC

This content is intended for healthcare professionals in Brazil, Germany and Spain only.

Please confirm that you are a healthcare professional in one of those countries.

Continue
Decline

This activity has been funded by Eli Lilly and Company Ltd.

Eli Lilly and Company Ltd. provided financial support and content, and has had input into the detailed project scope. This activity is provided by touchMEDICAL for touchONCOLOGY.

Close Popup
touchONCOLOGY
touchINFOGRAPHIC

Access to this content is only permitted for healthcare professionals in Brazil, Germany and Spain.

Back to touchONCOLOGY
Close Popup
touchONCOLOGY
touchINFOGRAPHIC

This content is intended for healthcare professionals in Brazil, Germany and Spain only.

Please confirm that you are a healthcare professional in one of those countries.

Register
Login

To access this content.

This activity has been funded by Eli Lilly and Company Ltd.

Eli Lilly and Company Ltd. provided financial support and video content, and has had input into the detailed project scope. This activity is provided by touchMEDICAL for touchONCOLOGY.

Close Popup
touchONCOLOGY

Could not verify Country/IP Address.

We were unable to verify your IP address, please try again later. If you are using a method to hide your IP address, such as a VPN or proxy, please disable this and try again.

Return to Homepage

This activity has been funded by Eli Lilly and Company Ltd.

Eli Lilly and Company Ltd. provided financial support and content, and has had input into the detailed project scope. This activity is provided by touchMEDICAL for touchONCOLOGY.

No endorsement by Eli Lilly or touchMEDICAL of any unapproved products or unapproved uses is either made or implied by mention of these products or uses in touchMEDICAL activities. touchMEDICAL accepts no responsibility for errors or omissions.

This material is intended exclusively for healthcare professionals.
Material destinado exclusivamente a profissionais da saúde prescritores e dispensadores de medicamentos.
Material dirigido exclusivamente a profesionales de la salud.

MMAT-05343; MMAT-05362; MMAT-05087
Date of preparation: July 2026

Latest articles videos and clinical updates - straight to your inbox

Close Popup